An observational study in Ventricular Tachycardia, sponsored by Mid and South Essex NHS Foundation Trust. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.
Sponsored by Mid and South Essex NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Tachycardia, Ventricular with a site in United Kingdom — 12 open to participants now, 14 under way, none of them phase 3. Tachycardia, Ventricular · United Kingdom.
Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2022, is one of 14 observational ones, reaches primary completion later than 3 of the 13 other live ones, and was the 29th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →12 of the 38 studies in Tachycardia, Ventricular with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Warwick · Sites in United Kingdom
Ages 18+
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–85
University Hospitals Coventry and Warwickshire NHS Trust · Sites in United Kingdom
Ages 18+
University Hospital, Basel, Switzerland · Sites in United Kingdom, United States, Austria and 13 more countries
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 70 is below the median of 167 across 147 observational studies indexed under Tachycardia, Ventricular.
Median enrollment 94 across the 24 interventional studies, 98 across the 14 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 38 have an industry lead sponsor. The 10 most frequent:
Mid and South Essex NHS Foundation Trust is the lead sponsor of 34 studies on the registry; 10 are open to participants now.
Mid and South Essex NHS Foundation Trust has 1 study filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
5 of the studies in Tachycardia, Ventricular with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04499326Barts & The London NHS TrustImproving Patient Reported Outcome Measures in Catheter Ablation | 2026-12-31 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
| NCT06384599Adagio MedicalVT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study | 2027-05-01 |
| NCT07759427University of WarwickUsing Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this registry database is to demonstrate the safety and effectiveness of functional ventricular tachycardia (VT) ablation using SENSE protocol in patients with ischaemic VT. Mortality and the need for ICD therapies at 12 months post-ablation will be compared with propensity-matched controls undergoing substrate-based ablation alone.
This is an international multicentre prospective registry. Participating centres will collect data during the pre-assessment, procedure, and follow-up visits at 6 and 12 months, according to standard practice. It is anticipated that the enrolment duration will be approximately 12 months, with the data being matched with that collected from a control group of patients undergoing conventional Ventricular tachycardia ablation methods.
Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One of the following VT events (within the last 6 months) + \<40%:
A: ≥3 episodes of VT treated with anti-tachycardia pacing (ATP), at least one of which is symptomatic.
B: ≥1 appropriate ICD shock. C: ≥3 VT episodes within 24 hr. D: Sustained VT below the detection rate of the ICD.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite of cardiovascular mortality and ICD therapy
Composite of cardiovascular mortality and implantable cardioverter-defibrillator (ICD) therapy
Time frame: 12 months
Length of hospital stay
Length of hospital stay
Time frame: 1 month
Left ventricular function on echocardiogram
Left ventricular function on echocardiogram
Time frame: 6 months
Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.
Of 69 observational studies under Tachycardia, Ventricular, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 108. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mid and South Essex NHS Foundation Trust